MENLO PARK, Calif., Feb. 27, 2025 /PRNewswire/ -- MyOme, Inc., a leading clinical whole genome testing and polygenic risk modelling (PRS) company, is proud to announce the launch of its coronary ...
Assuming the COMPASS results are enough to convince regulators to make the low dose of rivaroxaban used in the study available to clinicians, the trial should influence how patients with stable ...
The University of Pennsylvania (Penn), a world-renowned academic research and medical center with a history of innovation, was announced as the first site for the COMPASS-CAD trial, a prospective ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback